866318-99-2

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 5-fluoro-1-[(4-methylphenyl)sulfonyl]-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 5-fluoro-1-[(4-methylphenyl)sulfonyl]-;5-fluoro-1-tosyl-1H-pyrrolo [2,3-b]pyridine;5-fluoro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine
• CAS NO: 866318-99-2
• Molecular Formula: C₁₄H₁₁FN₂O₂S
• Molecular Weight: 290.31
• Mol File: 866318-99-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 473.2°C at 760 mmHg
• Flash Point: 240°C
• Appearance: /
• Density: 1.38g/cm³
• Vapor Pressure: 4.02E-09mmHg at 25°C
• Refractive Index: 1.641
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 5-fluoro-1-[(4-methylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 5-fluoro-1-[(4-methylphenyl)sulfonyl]-(866318-99-2)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 5-fluoro-1-[(4-methylphenyl)sulfonyl]-(866318-99-2)

Safety Data

• Hazardous Substances Data: 866318-99-2(Hazardous Substances Data)

Usage

Chemical structure

1H-Pyrrolo[2,3-b]pyridine derivative
A compound based on a pyrrolopyridine core structure, which is a fusion of a pyrrole and a pyridine ring.

Substituent

5-fluoro-1-[(4-methylphenyl)sulfonyl]
A functional group attached to the core structure, consisting of a fluorine atom at the 5-position, a sulfonyl group connected to a 4-methylphenyl ring, and an additional carbon atom.

Potential applications

Medicinal chemistry and drug discovery
The compound has diverse biological activities, making it a promising candidate for the development of new drugs and therapies.

Pharmacological property modification

5-fluoro-1-[(4-methylphenyl)sulfonyl] group
The presence of this group allows for the optimization of the compound's pharmacological properties, making it suitable for various therapeutic applications.

Specific uses and effects

Context-dependent and require further research
The exact applications and effects of the compound will depend on the specific context in which it is used and the results of additional research and development.

InChI:InChI=1/C14H11FN2O2S/c1-10-2-4-13(5-3-10)20(18,19)17-7-6-11-8-12(15)9-16-14(11)17/h2-9H,1H3

Upstream product

• 866319-01-9 5-fluoro-3-(2-trimethylsilylethynyl)pyridine-2-amine 
• 98-59-9 p-toluenesulfonyl chloride 
• 936344-74-0 3-ethynyl-5-fluoro-pyridin-2-ylamine 
• 823218-51-5 5-fluoro-3-iodo-pyridin-2-amine 
• 21717-96-4 2-amino-5-fluoropyridine 
• 869557-43-7 3-bromo-5-fluoropyridin-2-amine 
• 866319-00-8 5-fluoro-1H-pyrrolo[2,3‐b]pyridine 

Downstream Products

• 1417421-99-8 3-bromo-5-fluoro-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1629869-44-8 pimodivir 
• 1259279-57-6 5-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 866318-97-0 2-(5,6-dimethoxy-1H-indol-3-yl)-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 866318-98-1 5-fluoro-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

FORMULATIONS OF AZAINDOLE COMPOUNDS

The present invention relates to pharmaceutical compositions, each comprising a multitude of granules that make up an intragranular phase of the composition, wherein the granules are produced by fluid bed granulation and comprise a HCI salt of Compound (1

METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION

A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (X): a pharmaceutically acceptable salt thereof with Compound (Y): in the presence of a palladium catalyst and a carbonate or phosphate base

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.